An important addition to the bright future of Teva.
Eli Lilly's Cymbalta goes generic in December. Sales of Cymbalta by Lilly are expected to fall from about $5B to $1.5B about 70% drop in sales. Lilly's Evista will go generic in March 2014, with Teva being one of two companies holding 180 days of exclusivity in the U.S. Lilly's sales estimated at about $400M, a drop of about 50%. All these facts seem to predict a bleak outlook for Lilly and an important addition to the bright future of Teva.